CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance

Devin Oglesbee, PhD1, Tina M. Cowan, PhD2, Marzia Pasquali, PhD3, Timothy C. Wood, PhD4, Karen E. Weck MD5, Thomas Long, MPH6, Glenn E. Palomaki, PhD7 and on behalf of the College of American Pathologists and American College of Medical Genetics and Genomics, Biochemical and Molecular Genetics Resource Committee

**Purpose:** Testing for inborn errors of metabolism is performed by clinical laboratories worldwide, each utilizing laboratory-developed procedures. We sought to summarize performance in the College of American Pathologists’ (CAP) proficiency testing (PT) program and identify opportunities for improving laboratory quality. When evaluating PT data, we focused on a subset of laboratories that have participated in at least one survey since 2010.

**Methods:** An analysis of laboratory performance (2004 to 2014) on the Biochemical Genetics PT Surveys, a program administered by CAP and the American College of Medical Genetics and Genomics. Analytical and interpretive performance was evaluated for four tests: amino acids, organic acids, acylcarnitines, and mucopolysaccharides.

**Results:** Since 2010, 150 laboratories have participated in at least one of four PT surveys. Analytic sensitivities ranged from 88.2 to 93.4%, while clinical sensitivities ranged from 82.4 to 91.0%. Performance was higher for US participants and for more recent challenges. Performance was lower for challenges with subtle findings or complex analytical patterns.

**Conclusion:** US clinical biochemical genetics laboratory proficiency is satisfactory, with a minority of laboratories accounting for the majority of errors. Our findings underscore the complex nature of clinical biochemical genetics testing and highlight the necessity of continuous quality management.

*Genet Med* advance online publication 29 June 2017

**Key Words:** analytic sensitivity; biochemical genetics; clinical sensitivity; inborn errors of metabolism; proficiency testing

---

**INTRODUCTION**

Clinical biochemical genetics is a medical specialty devoted to diagnosing and treating inborn errors of metabolism (IEMs). IEMs encompass a heterogeneous group of genetic conditions including disorders of amino acid (AA; e.g., phenylketonuria), organic acid (OA; e.g., methylmalonic aciduria, MMA), mucopolysaccharide (MPS; e.g., Hurler syndrome), and fatty acid metabolism (e.g., medium-chain acyl-CoA dehydrogenase, MCAD, deficiency). Although individually rare, their estimated combined incidence is as high as 1:800–1:2,500 births. Symptoms often appear early in life, but clinical outcomes are optimized by an early diagnosis and therapy instigation before irreversible damage has occurred.

An IEM diagnosis is established through high-complexity, laboratory-developed tests performed by a relatively small number of laboratories worldwide, called clinical biochemical genetics laboratories (BGLs). Methods vary between laboratories, but they typically include high-pressure liquid chromatography, gas chromatography/mass spectrometry and/or liquid chromatography–tandem mass spectrometry (LC–MS/MS). There are no US Food and Drug Administration–cleared tests for biochemical genetics testing, a commonality shared with molecular genetics laboratories and DNA-based testing for rare heritable conditions. Despite the nonstandardized nature of laboratory testing, molecular genetic testing quality is very high. Nevertheless, biochemical genetic testing poses unique challenges to the clinical laboratory, including the innate task of assessing multiple analytes in a single test, and the inter- and intrapatient metabolic variability due to genotype, clinical status, or other intrinsic and extrinsic factors. Thus, it is vital that laboratories perform extensive validation and ongoing test monitoring to ensure the highest quality for patient care.

Participation in proficiency testing (PT) is associated with improved laboratory quality, particularly in the laboratory-developed test setting. External PT schemes for BGL testing were first introduced in the United States in the 1980s, with a review of outcomes highlighting the importance of ongoing training, education, and quality oversight in the area of IEM diagnosis. Comprehensive PT is also offered by the European Research Network for Evaluation and Improvement of Screening, Diagnosis and Treatment of Inherited Disorders of Metabolism (ERNDIM), which reported a positive correlation between participation and

---

1Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; 2Department of Pathology, Stanford University, School of Medicine, Palo Alto, California, USA; 3Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA; 4Greenwood Genetics Center, Greenwood, South Carolina, USA; 5Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 6Department of Biostatistics, College of American Pathologists, Northfield, Illinois, USA; 7Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Correspondence: Devin Oglesbee (ogleesbee.devin@mayo.edu)

Submitted 20 February 2017; accepted 31 March 2017; advance online publication 29 June 2017. doi:10.1038/gim.2017.61
laboratory quality. In 1993, the College of American Pathologists (CAP), in collaboration with the American College of American Genetics and Genomics (ACMG), introduced a BGL PT program that included the analysis of AAs, OAs, and MPS. The program was expanded in 2004 to include plasma acylcarnitine (AC) performance. Here, we present an analysis of the CAP/ACMG Biochemical Genetics Resource Committee PT program from more than 10 years of surveys (2004 through 2014). The analysis was restricted to laboratories that had participated in at least one PT survey since 2010. This was done to allow for estimates of recent laboratory performance, but it also permitted the examination of earlier PT performance in a subset of active laboratories.

MATERIALS AND METHODS
BGL proficiency testing survey
The PT survey consists of five specimens distributed twice yearly (an A and B distribution) to laboratories in the United States and abroad. Each mailing contained one specimen for every analysis, including plasma or urine AA, urine OA, plasma AC, and urine MPS. A fifth specimen, excluded from this analysis, is an ungraded educational challenge focusing on less frequently encountered areas of AA, OA, or AC testing. This report includes results from 21 BGL surveys from the 2004-B through 2014-B mailings.

Most specimens were authentic plasma or urine samples from patients with clinically confirmed diagnoses. Occasionally, samples were from unaffected individuals, pooled samples, or spiked with one or more compounds to mimic a metabolic disorder. All plasma samples used had negative test results for hepatitis B surface antigen, hepatitis C antibody, and HIV antigen/antibody. Challenges were pretested by multiple reference laboratories to verify suitability. Specimens were stored at −20 °C or lower, and aliquots were shipped on dry ice. A clinical history accompanied each challenge. Participants reported all diagnostically relevant analyte(s), the most likely diagnosis (clinical interpretation) based on analytic results and clinical history, and by selecting answers from a predefined list. Information about testing methodology and results of analyte quantitation were requested but not required or graded. Laboratories returned results within 30 days via an online result submission form or facsimile.

Data collection and analysis
Data were extracted from the CAP data management system and de-identified. These data encompassed participant results, including those returned after the required submission date and excluded from original Participant Summary Reports. Each challenge’s analytic and interpretative results were graded as “Acceptable” or “Unacceptable” based on participant consensus (>80%) or, in a few instances, on the consensus of reference laboratory results. Missing analytic results or missing clinical interpretations were not graded and were excluded from analysis. Members of the CAP/ACMG Biochemical and Molecular Genetics Resource Committee reviewed results and approved grading criteria. Acceptable results were based on either the identification of a well-recognized, analytical profile, or a pathognomonic analyte level, depending on the circulated specimen, and correlation with the provided clinical scenario. A two-dimensional matrix of the graded responses stratified by time (columns) and participants (rows) was created. These “heat maps” were used to compute analytic sensitivity (the proportion of abnormal analytes correctly identified) and clinical sensitivity (the proportion of disorders correctly diagnosed) for all challenges.

Calculations of clinical sensitivity included separate analyses for two types of false-negative results. One type occurs when participants recognize a specimen as having an abnormal clinical interpretation but report the incorrect disorder (i.e., not the intended response). The second type occurs when participants fail to recognize any clinical disorder and interpret the result as “Normal, unaffected.” This latter type is the classic false negative. The MPS survey had multiple challenges from unaffected individuals (six in total) and these were used to calculate analytic specificity (the proportion of normal specimens with no abnormal analytes reported) and clinical specificity (the proportion of normal specimens correctly diagnosed as normal). Rates were compared using the chi-squared test with a two-tailed significance level of 0.05. The 95% confidence intervals for proportions were computed using the adjusted Wald asymptotic method.

RESULTS
Participants and tests challenged
A total of 150 laboratories participated in the program for at least one of the AA, OA, AC, and MPS challenges since 2010, including 97 US and 53 international laboratories (North America, South America, Asia, and Europe). Of these, 35 (23%) reported results for all four schemes (AA, OA, AC, and MPS), while 49 (33%) participants reported results for only three schemes (25 for AA, OA, and AC and 23 for AA, OA, and MPS). Among the 38 (25%) participants reporting results for two schemes, the most common pair was AA and OA (26 participants) and among the 28 (19%) reporting results for only one scheme, the most common was AA (22).

AA proficiency testing
The AA challenges included specimens from individuals with phenylketonuria, maple syrup urine disease, various urea cycle defects, cystinuria, and other AA transport disorders (Supplementary Table S1 online). Results from 2013-A were excluded due to sample degradation likely related to storage. A total of 141 laboratories (91 US, 50 international) provided responses, with the number of participants remaining essentially constant since 2010 at around 95 participants. Most participants (75% in 2010) used AA analyzers, but this proportion dropped to 68% in 2014. LC-MS/MS was reported by three laboratories in 2010 and by nine laboratories in 2014.

AA PT results are summarized in the heat map (Figure 1), which includes participant-specific performance over time for both analytic and clinical interpretations (see also
Supplementary Figure S1). The overall analytic sensitivity for AA testing was 93.4% (1,552/1,661 responses), with the highest sensitivities (100%) observed for conditions related to phenylalanine, citrulline, and arginine metabolism, and the lowest for abnormalities in β-alanine (87.3%) and α-aminoadipic acid (86.2%). Stratified by geographic region, the analytic sensitivity was higher ($P < 0.001$) among US (95.1%, 1,122/1,180) than among international participants (89.4%, 430/481). Among US participants, 53 (58%) had no incorrect responses for analytic sensitivity. Four of these 91 laboratories (4%) accounted for 14 errors (between 3 and 6 each), representing 24% of all analytical errors. Among international participants, 23 (46%) had no incorrect responses for analytic sensitivity; six of these 50 laboratories (12%) accounted for 22 errors (between 3 and 5 each) representing 43% of all analytic errors.

The overall clinical sensitivity for all participants was 91.0% (1,514/1,663), but the clinical sensitivity was significantly higher among US participants (92.9%; 1,103/1,188) than international participants (86.5%; 411/475) ($P < 0.001$). Clinical sensitivity was highest for more easily recognizable conditions (phenylketonuria, 100%) and lowest for combined homocystinuria/methylmalonic aciduria (2008A, 76.3%). Despite compelling clinical scenarios, clinical sensitivity was also lower for several challenges where the differential diagnosis was broad, including 83.6% for homocystinuria (2006A, cystathionine-β-synthase deficiency) and 84.0% for primary lactic acidemia (2008B). Incorrect clinical interpretations were stratified by incorrect diagnosis (e.g., a sample with elevated citrulline mistakenly diagnosed as ornithine transcarbamylase deficiency rather than citrullinemia) versus “normal” clinical interpretation. This latter group of false negatives represented 2.6% (44/1,663) of all interpretations over the 10-year period. Among US laboratories, the rate of 2.4% (29/1,188) was not different from the 3.2% (15/475) found among international laboratories ($P = 0.41$). Since 2010, however, laboratories have improved with only one false-negative result occurring in more than 850 distinct clinical interpretations. A summary of AA performance results along with 95% confidence intervals is provided in Table 1.

Two challenges with a maple syrup urine disease specimen were distributed in 2005 and 2011. Leucine quantitation (Figure 2a) was 18% lower in the later distribution (443 vs. 430/481).
Table 1 Estimates of analytic sensitivity for the four schemes included in the biochemical genetic laboratories proficiency testing program stratified by laboratory location

| Scheme                      | Location | Analytic true positive | Analytic false negative | P value |
|-----------------------------|----------|------------------------|-------------------------|---------|
| Amino acids                 | US       | 95.1% (1,122/1,180)    | 4.9% (58/1,180)         | <0.001  |
|                             | International | 89.4% (430/481)       | 10.6% (51/481)          |         |
| Organic acids               | US       | 93.5% (942/1,007)     | 6.5% (65/1,007)         | 0.043   |
|                             | International | 90.4% (369/408)      | 9.6% (39/408)           |         |
| Acylcarnitine profile       | US       | 93.1% (471/506)       | 6.9% (35/506)           | 0.060   |
|                             | International | 88.9% (192/216)     | 11.1% (24/216)          |         |
| Mucopolysaccharides         | US (Screening) | 93.0% (318/342)   | 7.0% (24/342)           | 0.056   |
|                             | International | 88.2% (179/203)   | 11.8% (24/203)          |         |
|                             | US (Fractionation) | 91.4% (213/233) | 8.6% (20/233)          | 0.0010  |
|                             | International | 79.0% (94/119)     | 21.0% (25/119)          |         |

*Proportion of correct abnormal analyte identified (analytic sensitivity). bProportion of incorrect abnormal analyte identified, or no abnormal analyte identified. cComparison of analytic sensitivity between US and international participants.

The overall clinical sensitivity was 90.5% (1,301/1,437), and was significantly higher among US (92.9%; 947/1,019) than international (84.7%; 354/418) participants (P < 0.001). Interpretive performance was excellent for challenges that included specimens with prominent metabolite elevations and poor for challenges containing specimens with complex or subtle findings such as glutaric acidemia type II (2008B, 85.3%) or isobutyryl-CoA dehydrogenase deficiency (2006B, 75.0%). Among 73 US participants, 36 (49%) had no interpretive errors; 29 (40%) had one or two errors, and one laboratory accounted for nine errors. From 72 total errors, 43 (60%) reflected an incorrect diagnosis and 29 (40%) were false negatives (normal diagnosis). Among 40 international participants, 12 (30%) had no incorrect clinical interpretations, but two had four errors and one had five errors. In this group, there were 64 errors, of which 35 (55%) were incorrect diagnoses but 29 (45%) were identified as normal.

A single OA specimen of fumarase deficiency was distributed in 2005 and 2011, with quantitative data reported by 25 and 30 participants, respectively (Figure 2b). Median fumaric acid concentrations were 451 and 457 mmol/mol creatinine for the 2005 and 2011 mailings, respectively. The
results indicate satisfactory agreement between participants reporting quantitative values. There were a handful of outliers, yet their results were still indicative of fumarase deficiency.

AC proficiency testing
AC challenges included disorders of fatty acid oxidation such as MCAD deficiency, very long-chain acyl-CoA dehydrogenase deficiency, and long-chain hydroxyacyl-CoA dehydrogenase deficiency, as well as primary carnitine transporter deficiency, and organic acidemias such as MMA and propionic acidemia (Supplementary Table S1). A total of 65 laboratories (42 US, 23 international) provided results, with the number of participants rising from 43 in 2010 to 52 in 2014. By 2014, all laboratories were using (LC-MS/MS) with 91% utilizing butyl esters and the remainder using methyl esters or underivatized compounds.

AC performance results are summarized in Tables 1 and 2 and in a heat map (Supplementary Figure S3). The overall analytic sensitivity was 91.8% (663/722), with 93.1% (471/506) in US laboratories and 88.9% (192/216) in international laboratories ($P = 0.083$). Analytic sensitivity was 100% for several challenges including MCAD, MMA/propionic acidemia, and a recent very long-chain acyl-CoA dehydrogenase deficiency challenge (2014A). The lowest analytic sensitivity (64.5%) was seen for the 2009A challenge of long-chain hydroxyacyl-CoA dehydrogenase deficiency. Among all 65 participants, 29 (45%) had no analytical errors. One or two errors were made by 19 (29%) and 12 (18%) participants, respectively. Five laboratories
Table 2 Estimates of clinical sensitivity for the four schemes included in the biochemical genetic laboratories proficiency testing program stratified by laboratory location, along with the rate of the two types of false-negative errors

| Schemes             | Location  | True positive | Incorrect disorder identified | No disorder found: normal | P value d |
|---------------------|-----------|---------------|-------------------------------|---------------------------|-----------|
|                     |           | Correct diagnosis |                               |                           |           |
| Amino acids         | US        | 92.9% (1,103/1,188) | (91.4–94.3%)                  | 4.7% (56/1,188)           | (3.5–5.9%) | 2.4% (29/1,188) | (1.6–3.3%) | <0.001   |
|                     | International | 86.5% (411/475) | (83.5–89.6%)                  | 10.3% (49/475)            | (7.6–13.1%) | 3.2% (15/475) | (1.6–4.7%) | <0.001   |
| Organic acids       | US        | 92.9% (947/1019)  | (91.4–94.5%)                  | 4.2% (43/1019)            | (3.0–5.5%) | 2.9% (29/1019) | (1.8–3.9%) | <0.001   |
|                     | International | 84.7% (354/418)  | (81.2–88.2%)                  | 8.4% (35/418)             | (5.7–11.0%) | 6.9% (29/418)  | (4.5–9.4%) |           |
| Acylcarnitine profile | US           | 90.1% (462/513)  | (87.5–92.7%)                  | 7.2% (37/513)             | (5.0–9.5%) | 2.7% (14/513) | (1.3–4.1%) | 0.0082   |
|                     | International | 83.2% (188/226)  | (78.3–88.1%)                  | 8.8% (20/226)             | (5.1–12.6%) | 8.0% (18/226) | (4.4–11.5%) |           |
| Mucopolysaccharides | US        | 88.3% (227/257)  | (84.4–92.3%)                  | 8.9% (23/257)             | (5.5–12.4%) | 2.7% (7/257)  | (0.7–4.7%) | <0.001   |
|                     | International | 72.1% (106/147)  | (64.6–79.4%)                  | 20.4% (30/147)            | (13.9–26.9%) | 7.5% (11/147) | (3.2–11.7%) |           |

*Proportion of participants correctly identifying the targeted disorder (clinical sensitivity). bProportion of participants incorrectly identifying a disorder other than the intended target. cProportion of participants incorrectly providing a normal response for a challenge with a specific disorder. dComparison of clinical sensitivity between US and international participants. *All false-negative results occurred prior to 2011.

For PT more than once, and for which results included quantitative AC values, concentrations for significant AC results are shown in Figure 2c,d. Broad interlaboratory variation was observed for glutarylcarnitine (C5DC) in 2005 (four results > 300 nmol/ml and 10 between 1 and 5 nmol/ml), with significant improvement in 2010 (one result of 189 nmol/ml and 32 between 1 and 5 nmol/ml). Interlaboratory variability was also observed for malonylcarnitine (C3DC) measurements obtained from a specimen submitted for challenges in 2008 and 2012 (Figure 2d). While there was high interlaboratory variability in both 2008 and 2012, one outlier was identified among the 19 laboratories participating in both challenges. The remaining results were highly correlated (N=18, r=0.84), indicating low intralaboratory variability and the need for further standardization efforts.

### MPS proficiency testing

MPS challenges included Hurler/Hunter (MPS-I/II, graded together), Sanfilippo (MPS-III), Morquio (MPS-IV), and Sly (MPS-VII) syndromes, as well as six normal individuals (Supplementary Table S1). Results were reported for a screening assay for total MPS and/or a fractionation assay (elevations of keratan sulfate, dermatan sulfate, heparan sulfate, and chondroitin sulfate). Overall, 72 laboratories (42 US and 30 international) participated in the PT. Dimethylmethylene blue binding assay (50%) was the most common screening method, followed by toluidine blue (16%), Berry spot test (11%), and Alcian blue spot test (5%). Thin-layer chromatography and electrophoresis were reported among fractionation methods in similar frequencies, but LC-MS/MS increased to 11% by 2014.

MPS performance is summarized in Tables 1 and 2 and in a heat map (Supplementary Figure S1). Two MPS-VII samples (2008A, 2011A) were excluded from analysis due to the lack of participant consensus (<80%). The combined analytic sensitivity for all screening methods was 91.2% (497/545) with similar (P=0.060) performance by US
concentrations seen in long-chain hydroxyacyl-CoA analytical findings (e.g., minimally elevated C16-OH AC). Performance waned when challenges involved more subtle genetic conditions such as phenylketonuria, MMA, and very abnormalities, including samples from patients with classic genetic conditions. Performance was excellent for diagnostic abnormalities and correctly interpreted corresponding genetic conditions. The vast majority of PT participants accurately identified assays was 87.2% (307/352) and performance was significantly higher (P = 0.001) for US (91.4%, 213/233) than for international (79.0%, 94/119) participants. The sensitivity of fractionation assays was highest for MPS-III (95.7%; 132/138) and lowest for MPS-IV (78.8%; 63/80). Screening assays were more sensitive than fractionation methods for detecting an MPS abnormality. In particular, discrepancies were noted between the screening and fractionation methods for the 2010A challenge of MPS-II (100 vs. 83%) and the 2010B challenge of MPS-IV (98 vs. 73%).

The overall clinical sensitivity was 82.4% (333/404), with a significant difference (P < 0.001) between US (88.3%, 227/257) and international (72.1%, 106/147) laboratories. Clinical sensitivity was highest among MPS-III (Sanfilippo syndrome) challenges (88.2%; 135/153). The MPS-VII (Sly syndrome) challenges were the most problematic; two PT challenges lacked consensus for grading and the third had an overall clinical sensitivity of 79.3% (23/29).

For screening assays, 86% of laboratories (62/72) made one or fewer analytical errors (56% had no errors, 31% had one error). In addition, 10 laboratories (14%) made two or more errors apiece and were responsible for 26 of the 48 errors (54%). For the 49 laboratories utilizing fractionation assays, 33% (16) had no errors and 51% (25) had one error. The remaining eight laboratories (16%) made two or more errors apiece and were responsible for 20 of 45 errors (44%). Of the 56 laboratories reporting interpretations, 70% (39/56) had none or one interpretative error. The remaining 17 (30%) laboratories with two or more errors were responsible for 70% (50/71) of the errors.

Analytic specificity, calculated from results of the six normal samples, was 99.6% (254/255) for the screening assay and 93.9% (139/148) for the fractionation assay. Stratifying fractionation results by laboratory location revealed an analytic specificity of 96.1% (99/103) among US and 88.9% (40/45) among international participants (P = 0.091). Overall, 85% (23/27) of US and 79% (15/19) of international laboratories had no analytic specificity errors. The corresponding clinical specificity was 89.0% (169/190) with no significant difference by laboratory location.

DISCUSSION

The vast majority of PT participants accurately identified diagnostic abnormalities and correctly interpreted corresponding genetic conditions. Performance was excellent for challenges with prominent and characteristic biochemical abnormalities, including samples from patients with classic genetic conditions such as phenylketonuria, MMA, and very long-chain acyl-CoA dehydrogenase deficiency. In contrast, performance waned when challenges involved more subtle analytical findings (e.g., minimally elevated C16-OH AC concentrations seen in long-chain hydroxyacyl-CoA dehydrogenase deficiency), diagnoses relying on the recognition of a complex, multianalyte pattern (e.g., multiple acyl-Co dehydrogenase deficiency) and ultrarare conditions (e.g., mevalonic aciduria). Importantly, the proportion of participants completely missing a definitive diagnosis was low, and the majority of conditions were recognized as having abnormal biochemical profiles, even if the precise diagnosis provided was deemed unacceptable in the PT scheme.

Among the selected laboratories, performance over this study period was steadily higher among US laboratories than international laboratories. The reason for this tendency is unknown. Several factors between laboratories may account for this correlation. In particular, there exist specialized US laboratories (Clinical Biochemical Genetic Laboratories) devoted to the diagnosis and management of IEMs, and the United States has accredited training for clinical biochemical genetic laboratory directors, overseen by the American Board of Medical Genetics and Genomics, that aims to ensure excellence among laboratory directors through continuing education, among other activities. International laboratories may not have access to accredited training programs. Additionally, the distribution of PT specimens may face sporadic delays occurring during shipment to distant destinations thereby affecting sample integrity and impacting interpretation. Indeed, participating laboratories are requested to ensure that specimens arrive frozen and within their storage requirements. Nevertheless, adherence to this request relies on self-reported observations that may be hindered by storage, unpacking, and repackaging at custom office locations. Finally, rare disease incidence differences among populations worldwide may lead to the occurrence that a common genetic condition in one part of the world is seldom observed, if at all, in another region. Hence, laboratories can have divergent experiences with the full spectrum of IEMs. Thus, difference in performance may be due to a combination of these or other factors.

Because multiple factors probably contributed to performance variance for both US and international laboratories, a central function of PT is to prompt assay troubleshooting, process refinement, and quality improvement when failures do occur. This includes prompting laboratories to review their processes for analyte extraction and derivatization, method calibration, and instrument optimization. Analytic errors may also reflect limitations in available laboratory methods, such as for MPS screening and fractionation where assay shortcomings are well recognized and addressed by emerging new LC-MS/MS methods. Some errors may result from constraints inherent to the PT process itself, where lower estimates of clinical sensitivity may be due to the lack of supporting clinical information or results of other laboratory tests. This underscores the importance of clinical history when interpreting analytic findings, as pointed out by other groups. Finally, because laboratories submit PT results outside of their normal data transmission and reporting protocols, inadvertent clerical errors may also occur.

Incorrect interpretations also may have resulted from the strict requirement to report a specific diagnosis, even in cases...
ORIGINAL RESEARCH ARTICLE

for which additional testing may be warranted in actual practice. For example, a suspected case of MCAD deficiency identified by OA analysis typically requires additional confirmation by AC analysis, and positive MPS screening and fractionation results require confirmation by enzyme and/or DNA testing.21 Responses representing an incorrect diagnosis (as opposed to a “normal” response in the face of a true abnormality) were classified as false-negative results for this report. Although considered a PT failure, in practice an incorrect diagnosis still is likely to be followed by repeat testing, additional studies, or gathering of additional clinical or family history. Indeed, some diagnoses included in PT schemes, such as carnitine uptake defect (an AC challenge) or glycine encephalopathy (a plasma AA challenge), may have been particularly challenging since these conditions are more appropriately diagnosed in conjunction with other tests (free and total carnitine and cerebrospinal fluid AA analysis, respectively). Nonetheless, despite the inherent constraints of PT, a correct diagnosis could most often unequivocally be assigned based on results of a single test.

Among other PT programs available for BGLs, the European consortium ERNDIM provides challenges for qualitative OA and urine MPS schemes that are similar to the CAP/ACMG program. As a comparison, reported ERNDIM performance (see http://www.erndim.org/home) for 2015 showed that accuracy ranges from 60 to 89% for MPS and 85 to 100% for OA. Hence, the PT performance of laboratories observed in the CAP/ACMG scheme is similar to those found in other programs.

From this study, current clinical biochemical genetic laboratories demonstrated good overall performance on PT. Remaining challenges for laboratories include the need for standardizing laboratory methods and reagents, and ensuring that ongoing education enhances the awareness of genetic disorders, and their diagnostic profiles, thereby benefiting patient care.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at http://www.nature.com/gim

ACKNOWLEDGMENTS

We thank Pamela Provax (employee of the College of American Pathologists, Northfield, IL) for providing support. We also thank previous Biochemical Genetics Subcommittee members and patient donors who graciously provided authentic specimens to assess and improve laboratory quality.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;105:e10.
2. Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child 2006;91: 896–899.
3. Berry SA. Newborn screening. Clin Perinatol 2015;42:441–453.
4. Press RD, Eickelberg G, McDonald TJ, et al. Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists. Genet Med 2016;18:1206–1213.
5. Lyon E, Schrijver I, Weck KE, et al. Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys. Genet Med. 2015;17:219–225.
6. Tafe LE, for the CAP/ACMG Biochemical and Molecular Genetics Resource Committee. Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys. Genet Med 2015;17:58–62.
7. Feldman GI, for the CAP/ACMG Biochemical and Molecular Genetics Resource Committee. Results of the College of American Pathology/American College of Medical Genetics and Genomics external proficiency testing from 2006 to 2013 for three conditions prevalent in the Ashkenazi Jewish population. Genet Med 2014;16:695–702.
8. Richards CS, Palomaki GE, Lachbawan FL, et al. Three-year experience of a CAP/ACMG methods-based external proficiency testing program for laboratories offering DNA sequencing for rare inherited disorders. Genet Med 2014;16:25–32.
9. Weck KE, for the CAP/ACMG Biochemical and Molecular Genetics Resource Committee. Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001-2009). Genet Med 2012;14:306–312.
10. Palomaki GE, Richards CS. Assessing the analytic validity of molecular testing for Huntington disease using data from an external proficiency testing survey. Genet Med 2012;14:69–75.
11. Richards CS, Palomaki GE, Hegde M. Results from an external proficiency testing program: 11 years of molecular genetics testing for myotonic dystrophy type 1. Genet Med 2016;18:1290–1294.
12. McGovern MM, Benach M, Wallenstein S, Boone J, Lubin IM. Personnel standards and quality assurance practices of biochemical genetic testing laboratories in the United States. Arch Pathol Lab Med 2003;127:71–76.
13. Hudson KL, Murphy JA, Kaufman DJ, Jawitt GH, Katsanis SH, Scott J. Oversight of US genetic testing laboratories. Nat Biotechnol 2006;24:1083–1090.
14. Tan IK, Gajra B, Lim MS. External proficiency testing programmes in laboratory diagnoses of inherited metabolic disorders. Ann Acad Med Singapore 2006;35:688–693.
15. Hommes FA, Brewster MA, Burton BK, et al. Proficiency testing for biochemical genetics laboratories: the first 10 rounds of testing. Am J Hum Genet 1990;46:1001–1004.
16. Hommes FA. Quality control for selective screening of inborn errors of metabolism. Eur J Pediatr 1994;153(7 Suppl 1):S17–S22.
17. Fowler B, Burlina A, Kozich V, Vianey-Saban C. Quality of analytical performance in inherited metabolic disorders: the role of ERNDIM. J Inherit Metab Dis 2008;31:680–689.
18. Lukacs Z. Mucopolysaccharidases. In: Blau N, Duran, M, Gibson, MK (eds). Laboratory Guide to the Methods in Biochemical Genetics. Springer: Berlin, 2008:297–324.
19. Auray-Blais C, Bherer P, Gagnon R, et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses types I, II and VI. Mol Genet Metab 2011;102:49–56.
20. Martell LA, Cunico RL, Ohj J, Fullerson W, Furneaux R, Foehr ED. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 2011;3:1855–1866.
21. Centers for Disease Control and Prevention. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. MMWR Recomm Rep 2012;61(RR-2):1–44.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/